Markets:

Overview

News

Currencies

International

Treasuries

Vertex Pharmaceuticals (NQ:VRTX)

469.27 UNCHANGED

Streaming Delayed Price Updated: 4:00 PM EST, Feb 19, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Vertex Pharmaceuticals

< Previous 1 2

...

29 30 31 32 33 34 35 36 37

...

63 64 Next >

Vertex Pharmaceuticals (VRTX) Q3 2023 Earnings Call Transcript ↗

November 07, 2023

VRTX earnings call for the period ending September 30, 2023.

Via The Motley Fool

Topics Earnings

Cathie Wood's ARK Innovation Just Had Its Best Week Ever Thanks To Roku, These Huge Winners ↗

November 06, 2023

Roku vaulted 50% to become Ark Innovation's top holding.

Via Investor's Business Daily

Earnings Scheduled For November 6, 2023 ↗

November 06, 2023

Companies Reporting Before The Bell • Kosmos Energy (NYSE:KOS) is expected to report quarterly earnings at $0.16 per share on revenue of $366.82 million.

Via Benzinga

US Stocks Set To Extend 5-Day Winning Streak Today? Traders Anxiously Watch Fed Speech, Climbing Bond Yields ↗

November 06, 2023

The market looks set to extend last week’s gains, with the stock futures holding up early Monday ahead of a slew of earnings reports mostly from the small and mid-cap space.

Via Benzinga

Topics Economy

Exploring NASDAQ:VRTX's quality characteristics. ↗

October 30, 2023

Reasonable Growth, Debt Levels, and a High ROIC Make VERTEX PHARMACEUTICALS INC (NASDAQ:VRTX) Appealing to Quality Investors.

Via Chartmill

Fed Holds Rates Steady, Powell's Cautious Stance Soothes Investors, Labor Market Softens: The Week In The Markets ↗

November 03, 2023

Markets bounced back decisively this week, shrugging off prior volatile months marked by heightened geopolitical tensions. The resurgence of risk sentiment ignited a relief rally in both equities and...

Via Benzinga

Topics Bonds Economy

Stock Market Rally Back In Force As Treasury Yields Plunge; Arista, Palantir Among Winners: Weekly Review ↗

November 03, 2023

Bulls are back in control as the major indexes confirmed the uptrend this week.

Via Investor's Business Daily

Here's What Investors Need to Know About Vertex Pharmaceuticals and CRISPR Therapeutics' Big Day at the FDA ↗

November 03, 2023

The meeting went almost as well as could be expected.

Via The Motley Fool

One Month Ahead of its Most Crucial Moment Ever, Should You Buy CRISPR Therapeutics? ↗

November 02, 2023

This stock could be a long-term winner, thanks to its game-changing technology.

Via The Motley Fool

Here's How Much $100 Invested In Vertex Pharmaceuticals 10 Years Ago Would Be Worth Today ↗

November 01, 2023

Via Benzinga

Crispr Therapeutics Rallies On Bullish Views Of First-Ever Gene-Editing Drug ↗

November 01, 2023

The agency could soon approve a potential cure for sickle cell disease .

Via Investor's Business Daily

Apellis Pharmaceuticals Stock Improves With An RS Ratings Over 90 ↗

October 31, 2023

Apellis Pharmaceuticals shows improving price performance, earning an upgrade to its IBD Relative Strength Rating.

Via Investor's Business Daily

Gene Therapy Could Be On the Cusp of a Major Breakthrough, but Investors May Have to Remain Patient ↗

October 30, 2023

This gene-editing pioneer could make history this week. But shareholders should remain focused on the long term.

Via The Motley Fool

Want $1 Million in Retirement? Invest $250,000 in These 3 Stocks and Wait a Decade ↗

October 28, 2023

4x returns in just a decade is quite an attainable result for these companies.

Via The Motley Fool

CRSP Stock: FDA Considers Additional Review of CRISPR Therapeutics Gene Therapy ↗

October 27, 2023

Although CRISPR Therapeutics may have a breakthrough drug on its hands, regulatory concerns hang over CRSP stock.

Via InvestorPlace

Rocket Pharmaceuticals Stock Sees RS Rating Pops Higher ↗

October 27, 2023

A Relative Strength Rating upgrade for Rocket Pharmaceuticals shows improving technical performance. Will it continue?

Via Investor's Business Daily

Questions Surround Vertex/CRISPR's Sickle Cell Gene Therapy As FDA AdComm Meeting Approaches ↗

October 27, 2023

The FDA's Cellular, Tissue, and Gene Therapies Advisory Committee will meet next

Via Benzinga

Got $1,000? 3 Growth Stocks to Buy That Could Double Your Money ↗

October 27, 2023

These companies come from very different industries, but each has businesses that investors may find compelling.

Via The Motley Fool

IBD's 100 Best ESG Companies For 2023 ↗

October 27, 2023

The companies on our list combine high sustainability scores and top stock ratings.

Via Investor's Business Daily

2 Healthcare Stocks That Could Make You Richer ↗

October 27, 2023

The need for healthcare is consistent and ongoing, a reality that makes this industry resilient to economic downturns.

Via The Motley Fool

2 Top Healthcare Stocks Defying the Bear Market ↗

October 26, 2023

These companies are building out their revenue and profit streams, and the proof is in the pudding.

Via The Motley Fool

This Market-Beating Growth Stock Is Set to Outperform Yet Again in 2024 ↗

October 26, 2023

This rare disease company is on a roll.

Via The Motley Fool

2 Best Healthcare Stocks to Buy Right Now ↗

October 26, 2023

The healthcare industry is an explosive space full of promising, profitable companies.

Via The Motley Fool

Vertex Pharmaceuticals: Buy at the High? ↗

October 26, 2023

Vertex shares have been flying high in recent times.

Via The Motley Fool

3 Healthcare Stocks to Buy and Hold for the Next 10 Years ↗

October 26, 2023

Great healthcare businesses are out there and their stocks are ripe for the picking.

Via The Motley Fool

2 No-Brainer Growth Stocks to Buy Right Now ↗

October 26, 2023

These businesses are thriving and raking in profits.

Via The Motley Fool

2 Fantastic Growth Stocks to Buy Hand Over Fist ↗

October 26, 2023

These stocks make great bargains today.

Via The Motley Fool

3 Red-Hot Growth Stocks That Are Still Cheap Buys ↗

October 25, 2023

It's not too late to invest in these great businesses.

Via The Motley Fool

Apellis Pharmaceuticals Stock Shows Rising Relative Strength ↗

October 24, 2023

A Relative Strength Rating upgrade for Apellis Pharmaceuticals shows improving technical performance. Will it continue?

Via Investor's Business Daily

The Best Stocks to Invest $5,000 In Right Now ↗

October 24, 2023

Today, the following three healthcare players look like fantastic bargains.

Via The Motley Fool

< Previous 1 2

...

29 30 31 32 33 34 35 36 37

...

63 64 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Vertex Pharmaceuticals (NQ:VRTX)

Headline News about Vertex Pharmaceuticals

Starting at $3.75/week.

Subscribe Today